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Background: Optimal management of patients with upper rectal cancer remains unclear. Partial
mesorectal excision (PME) without neoadjuvant therapy is currently advocated for the majority of
patients. Recent studies, however, reported a high risk of local recurrence and suboptimal surgery. The
aim of this study was to evaluate the effects of a quality assurance initiative with postoperative MRI to
improve outcomes in these patients.
Methods: Patients who underwent mesorectal excision with curative intent for rectal cancer in
2007–2013 were included. Postoperative MRI of the pelvis was performed 1 year after surgery. In 2011,
a multidisciplinary workshop with focus on extent and completeness of surgery was held for training sur-
geons, pathologists and radiologists involved in treatment planning. Images of residual mesorectum and
histopathological reports were reviewed with regard to the distal resection margin. Local recurrence after
a minimum of 3 years’ follow-up was compared between two cohorts from 2007–2010 and 2011–2013.
Results: A total of 627 patients were included; postoperative MRI of the pelvis was done in 381 patients.
The 3-year actuarial local recurrence rate in patients with upper rectal cancer improved from 12⋅9 to 5⋅0
per cent (P =0⋅012). After the workshop, fewer patients with cancer of the upper rectum were selected to
have PME (90⋅8 per cent in 2007–2010 versus 80⋅2 per cent in 2011–2013; P =0⋅023), and fewer patients
who underwent PME had an insufficient distal resection margin (61⋅7 versus 31 per cent respectively;
P < 0⋅001).
Conclusion: Quality assessment of surgical practice may have a major impact on oncological outcome
after surgery for upper rectal cancer.
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Introduction
Management of rectal cancer has improved over recent
decades, primarily by the standardization and improve-
ment of surgical procedure. Whereas total mesorectal
excision (TME) or abdominoperineal excision (APE) is
optimal for mid and low rectal cancer, there has been little
focus on the optimal management of upper rectal can-
cer. Tumours of the upper rectum (more than 10–15 cm
from the anal verge) may not require TME, and may be
managed optimally by perpendicular transection of the
mesorectum at least 5 cm below the lower edge of the
tumour. Partial mesorectal excision (PME) is currently
advocated for the majority of tumours of the upper rec-
tum, based on the rationale that preservation of a distal
part of the rectum and mesorectum will result in better
long-term functional outcome and fewer postoperative
complications, and assumed similar oncological safety1–6.
Dedicated centres have reported local recurrence rates of
between 4 and 8 per cent following PME for upper rectal
cancer, without the use of neoadjuvant treatment, equal to
or better than the local recurrence rates for TME2,3,7,8.
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Standardization and quality assurance of mesorectal exci-
sion by training and pathological audit were implemented
in the major trials to ensure that optimal surgery was per-
formed. It is important, however, that outside the setting
of clinical trials standardization and assurance of best qual-
ity surgery are also sustained in routine clinical practice. By
using postoperative MRI it is possible to assess the extent
and completeness of mesorectal excision by focusing on the
tissue left behind, as opposed to tissue removed9,10.
A concerningly high rate of local recurrence (13⋅5 per
cent) in patients with upper rectal cancer after PME
has been reported previously11. Evidence of suboptimal
surgery and/or selection was clear9,11. Similarly, in stud-
ies from Germany and Sweden local recurrence rates in
patients with upper rectal cancer as high as 10–16 per cent
have been reported12–15. A difference of more than 10 per
cent in the local recurrence rate most likely reflects vari-
ations in the preoperative assessment, surgical technique
and/or use of neoadjuvant therapy.
The aim of this study was to assess the effect of a
multidisciplinary-initiated quality assurance programme in
patients treated for upper rectal cancer with regard to local
recurrence, type of surgery, residual mesorectum and distal
resection margin.
Methods
Consecutive patients with rectal adenocarcinoma, defined
as cancer 15 cm or less from the anal verge on rigid proc-
toscopy, who underwent mesorectal excision with curative
intent at Aarhus University Hospital or Regional Hospital
Randers, two hospitals in Denmark, from August 2007 to
2013 were included in the study cohort. All patients were
discussed at a multidisciplinary team (MDT) conference
based on preoperative MRI of the pelvis (if applicable), CT
of the chest and abdomen, and a clinical examination with
rigid proctoscopy.
Danish guidelines16 recommend a selective approach
in application of long-course chemoradiotherapy for rec-
tal cancer according to the stage and location of the
tumour discussed at an MDT conference. All patients with
resectable, cT1–2 upper, mid or low rectal cancer undergo
surgery directly, without neoadjuvant treatment. Patients
with a cT3 tumour of the mid rectum are allocated to
long-course preoperative radiochemotherapy if the dis-
tance from the tumour to the mesorectal fascia is less
than 5 mm on preoperative MRI. cT3–4 tumours of the
low rectum are all considered candidates for long-course
radiochemotherapy. In Denmark, only unresectable cancer
of the upper rectum is considered for neoadjuvant therapy.
Guidelines were unchanged during the study period.
Patients who had surgery without signs of distant
metastasis and with tumours considered to be resectable
with a clear margin at preoperative evaluation or after
neoadjuvant therapy were classified as having treatment
with curative intent, irrespective of the pathological cir-
cumferential resection margin (CRM) involvement at
definitive histopathological examination. Type of surgery
was determined from the surgical reports. Approval for the
study was obtained from the Local Committee for Health
Research Ethics and the Danish Data Protection Agency
(2009-41-4056).
Data collection and follow-up
The length of the distal resection margin (DRM) was
measured in all rectal cancer specimens at histopathological
examination. The length of the DRM was measured on
the fixed specimen after sectioning in 5-mm slices, as the
distance between the luminal lower border of the tumour
and the distal cut edge. A DRM of less than 3⋅5 cm in PME
resections was evaluated as insufficient based on findings of
a previous study17.
Tumour height had been documented by both rigid proc-
toscopy at preoperative evaluation and on preoperative
MRI. The height measured by rigid proctoscopy was set
as the method of reference. On MRI, tumour height was
measured as the distance between the lower border of the
subcutaneous part of the external sphincter, reflecting the
anal verge, and the most distal part of the luminal tumour.
Generally, patients were included in a follow-up regi-
men with outpatient visits at 3, 6, 12, 18, 24 and 36 months
after surgery. At each visit, a clinical examination and rigid
proctoscopy (not applicable in patients who had APE)
were performed. CT of the chest and abdomen was per-
formed according to the protocol for the COLOFOL
trial18 (NCT00225641) with frequent and less frequent
arms. Follow-up CT was performed at 12 and 36 months
in the less frequent arm and at 6, 12, 18, 24 and 36 months
in the frequent arm. A subset of elderly and co-morbid
patients were exempted from regular follow-up and were
not examined routinely for disease recurrence. Local recur-
rence was defined as a clinical, symptomatic, radiologically
evident tumour or biopsy-proven adenocarcinoma located
in the pelvis, regardless of the presence of distant metasta-
sis. Histological verification was not achieved in all patients
and was not considered a prerequisite for diagnosis.
Postoperative MRI
Consecutive patients were invited for postoperative MRI
of the pelvis. Patients with disseminated disease, previous
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diagnosis of local recurrence, death at inclusion or con-
traindication to MRI were not eligible. Patients had MRI
at least 6 months from the time of primary surgery.
MRI was performed using a Magnetom Avanto 1⋅5-Tesla
MRI Scanner® (Siemens, Erlangen, Germany). Sagittal,
axial and coronal T2-weighted turbo spin-echo images
were obtained in addition to a sagittal short T1-inversion
recovery of the bony pelvis and a sagittal T23D sequence
of the smaller pelvis. The radiologist was blinded to the
pathological assessment and all clinical data, with the
exception of preoperative MRI findings and type of surgery.
Evaluation of the postoperative MRI included assessment
for the presence, localization and size of residual mesorec-
tum, level of anastomosis and detection of local recurrence.
The same radiologist evaluated all radiological examina-
tions together with the first author for consensus. Mesorec-
tal fatty tissue with a discernible tissue interface of fibrosis,
which separates the mesorectum from the mesocolon, was
considered a sign of residual mesorectum and categorized
as described previously9. Only mesorectum above the level
of the anastomosis perpendicular to the bowel was regarded
as inadvertent residual mesorectum following PME.
Intervention
Quality assessment of surgery in the two departments has
been performed since 2007 by postoperative MRI and
histopathological examination. In 2011, an MDT-initiated
workshop with focus on the extent and completeness
of mesorectal excision was held with participation of all
involved surgeons, pathologists and radiologists. A spe-
cific focus was on upper rectal cancer and PME based
on postoperative MRI findings between 2007 and 2010. A
description of the procedure with comparison of preopera-
tive and postoperative images together with histopatholog-
ical section was presented. Documentation of inadvertent
residual mesorectum following mesorectal excision, length
of DRM, histopathological examination, and comparison
between tumour height on rigid proctoscopy and preoper-
ative MRI were reviewed and discussed in a plenary session.
After the workshop, quality assessment of treatment and
surgery continued by postoperative MRI and histopatho-
logical examination according to the same protocol.
Statistical analysis
Demographic and patient characteristics were summarized
using median (range) values and percentages, with com-
parisons performed using Student’s t test and the χ2 test for
continuous and categorical data respectively. Local recur-
rence rates were estimated using Kaplan–Meier actuarial
methods between the two time periods, 2007–2010 and
2011–2013. The log rank test was used for comparisons,
as well as for subanalysis in patients with tumours of the
upper rectum. Time to local recurrence was measured from
the date of primary surgery to the date of diagnosis of local
recurrence. Patients without local recurrence were cen-
sored on the date of their last outpatient visit or upon death.
Statistical analyses were performed using Stata® ver-
sion 12 (StataCorp, College Station, Texas, USA) and
SigmaPlot® (Systat Software, San Jose, California, USA).
P < 0⋅050 was considered to represent statistical signifi-
cance.
Results
A total of 627 patients underwent curative resection with
mesorectal excision for rectal adenocarcinoma between
2007 and 2013. Clinical characteristics of these patients
according to the two time periods are shown in Table 1. Dis-
tributions of age, sex, tumour stage and use of neoadjuvant
therapy were similar between the two periods, 2007–2010
and 2011–2013, but more patients had laparoscopic
surgery compared with open surgery in 2011–2013 (71⋅2
per cent versus 8⋅5 per cent in 2007–2010; P < 0⋅001). Of
the 627 patients, 381 (60⋅6 per cent) had postoperative MRI
performed a median of 12 months after primary surgery.
After a median follow-up of 36 (range 0⋅2–107) months,
42 patients developed local recurrence. The overall
3-year actuarial local recurrence rates in 2007–2010 and
2011–2013 were 7⋅3 (95 per cent c.i. 4⋅9 to 10⋅9) and
4⋅6 (2⋅5 to 8⋅4) per cent respectively (P = 0⋅156) (Table 2).
The risk of local recurrence was associated with advanced
tumour stage and an involved CRM. Distant metastatic
disease developed in 11⋅8 per cent, and did not differ
between the two time periods (12⋅7 versus 10⋅6 per cent
respectively; P = 0⋅454).
The risk of local recurrence in patients with cancer of
the upper rectum improved after the workshop, from 12⋅9
per cent in 2007–2010 to 5⋅0 per cent in 2011–2013
(P = 0⋅012) (Fig. 1). Subanalysis of the risk factors for local
recurrence in the group of patients with upper rectal cancer
is shown in Table 3.
Tumour location with regard to tumour height measured
by rigid proctoscopy did not differ between 2007–2010
and 2011–2013, with 38⋅8 and 38⋅3 per cent respectively of
tumours located in the upper rectum (P = 0⋅878) (Table 1).
All patients who underwent PME had a tumour located
more than 10 cm from the anal verge as measured by rigid
proctoscopy. Of patients who had PME in 2007–2010,
22⋅7 per cent of the tumours (29 of 128) were estimated
to be located in the mid rectum (5–10 cm from the anal
verge) on preoperative MRI (Figs 2 and 3). This decreased
to 5 per cent (4 of 81) in patients who underwent PME in
© 2019 The Authors. www.bjsopen.com BJS Open
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Table 1 Patient demographics, tumour and treatment
characteristics
2007–2010 2011–2013 P‡
No. of patients 363 264
No. who had postoperative MRI 212 (58⋅4) 169 (64⋅0) 0⋅160
Age (years)* 66 (31–92) 67 (40–91) 0⋅219§
Sex 0⋅742
M 218 (60⋅1) 156 (59⋅1)
F 145 (39⋅9) 108 (40⋅9)
Distance of primary tumour
from anal verge (cm)†
0⋅878
>10–15 141 (38⋅8) 101 (38⋅3)
>5–10 124 (34⋅2) 97 (36⋅7)
0–5 97 (26⋅7) 66 (25⋅0)
Missing 1 (0⋅3) 0 (0)
Preoperative radiotherapy 0⋅462
No 264 (72⋅7) 199 (75⋅4)
Yes 99 (27⋅3) 65 (24⋅6)
Type of surgery 0⋅174
PME 128 (35⋅3) 81 (30⋅7)
TME 126 (34⋅7) 111 (42⋅0)
APE 109 (30⋅0) 72 (27⋅3)
Surgical approach <0⋅001
Laparotomy 332 (91⋅5) 76 (28⋅8)
Laparoscopy 31 (8⋅5) 188 (71⋅2)
pT category 0⋅196
pT0–2 123 (33⋅9) 82 (31⋅1)
pT3 195 (53⋅7) 159 (60⋅2)
pT4 40 (11⋅0) 21 (8⋅0)
Missing 5 (1⋅4) 2 (0⋅8)
pN category 0⋅370
pN0 235 (64⋅7) 175 (66⋅3)
pN1–2 120 (33⋅1) 87 (33⋅0)
Missing 8 (2⋅2) 2 (0⋅8)
CRM 0⋅150
Negative 316 (87⋅1) 238 (90⋅2)
Positive 41 (11⋅3) 23 (8⋅7)
Missing 6 (1⋅7) 3 (1⋅1)
Plane of surgery 0⋅036
Muscularis propria 106 (29⋅2) 68 (25⋅8)
Intrarectal or mesorectal 243 (66⋅9) 192 (72⋅7)
Missing 14 (3⋅9) 4 (1⋅5)
Values in parentheses are percentages unless indicated otherwise; *values
are median (range). †Measured by rigid proctoscopy at preoperative clin-
ical evaluation. PME, partial mesorectal excision; TME, total mesorectal
excision; APE, abdominoperineal excision; CRM, circumferential resec-
tion margin. ‡χ2 test, except §Student’s t test.
2011–2013 (P = 0⋅024). After the workshop, fewer patients
with upper rectal cancer underwent PME compared with
TME; the rate of TME increased from 9⋅2 per cent in
2007–2010 to 19⋅8 per cent in 2011–2013 (P = 0⋅023).
No patient who had TME for cancer of the upper rectum
developed local recurrence (Table 3).
Table 2 Local recurrence rates according to treatment
characteristics in the two cohorts
3-year actuarial
local recurrence (%)
2007–2010 2011–2013 P*
All patients 7⋅3 (4⋅9, 10⋅9) 4⋅6 (2⋅5, 8⋅4) 0⋅156
Sex
M 7⋅2 (4⋅3, 12⋅2) 4⋅7 (2⋅2, 10⋅3) 0⋅926
F 7⋅4 (2⋅8, 11⋅9) 5⋅0 (1⋅9, 12⋅6) 0⋅528
Distance of primary tumour
from anal verge (cm)
>10–15 12⋅9 (8⋅0, 20⋅6) 5⋅0 (1⋅9, 12⋅9) 0⋅012
>5–10 1⋅9 (0⋅5, 7⋅6) 3⋅9 (1⋅3, 11⋅5) 0⋅083
0–5 6⋅1 (2⋅6, 14⋅1) 5⋅9 (1⋅9, 17⋅1) 0⋅835
Preoperative radiotherapy
No 8⋅5 (5⋅5, 13⋅1) 5⋅1 (2⋅6, 9⋅9) 0⋅681
Yes 3⋅9 (1⋅3, 11⋅4) 3⋅9 (1⋅0, 14⋅8) 0⋅936
Type of surgery
PME 13⋅3 (8⋅1, 21⋅4) 6⋅3 (2⋅4, 15⋅8) 0⋅028
TME 2⋅9 (0⋅9, 8⋅6) 3⋅5 (1⋅1, 10⋅2) 0⋅159
APE 5⋅6 (2⋅3, 12⋅8) 5⋅4 (1⋅8, 15⋅7) 0⋅825
Surgical approach
Laparotomy 7⋅3 (4⋅8, 11⋅1) 5⋅0 (1⋅6, 14⋅7) 0⋅842
Laparoscopy 7⋅7 (1⋅9, 27⋅4) 4⋅8 (2⋅3, 9⋅7) 0⋅819
pT category
pT0–2 1⋅9 (0⋅5, 7⋅4) 1⋅6 (0⋅2, 10⋅7) 0⋅613
pT3 8⋅1 (4⋅8, 13⋅5) 3⋅9 (1⋅6, 9⋅2) 0⋅354
pT4 22⋅6 (11⋅5, 41⋅6) 25⋅8 (10⋅6, 54⋅9) 0⋅883
CRM
Negative 6⋅1 (3⋅8, 9⋅7) 3⋅8 (1⋅8, 7⋅8) 0⋅576
Positive 19⋅1 (9⋅0, 37⋅6) 15⋅4 (5⋅2, 40⋅5) 0⋅993
Plane of surgery
Muscularis propria 9⋅4 (4⋅8, 17⋅8) 6⋅7 (1⋅0, 14⋅0) 0⋅965
Intramesorectal 3⋅7 (1⋅2, 11⋅0) 5⋅6 (2⋅1, 14⋅1) 0⋅423
Mesorectal 8⋅2 (4⋅5, 14⋅7) 5⋅2 (1⋅9, 13⋅2) 0⋅420
pN category
pN0 5⋅1 (2⋅8, 9⋅3) 4⋅4 (2⋅0, 9⋅6) 0⋅729
pN1 12⋅4 (6⋅4, 23⋅3) 9⋅6 (2⋅1, 17⋅0) 0⋅576
pN2 11⋅8 (5⋅0, 28⋅4) 9⋅5 (3⋅2, 26⋅7) 0⋅915
Values in parentheses are 95 per cent confidence intervals. PME, partial
mesorectal excision; TME, total mesorectal excision; APE, abdominoper-
ineal excision; CRM, circumferential resection margin. *Log rank test.
Of all patients who underwent PME, the DRM measured
at histopathological examination was reported to be less
than 3⋅5 cm in 49⋅8 per cent (104 of 209). This improved
in the later cohort, with a decrease from 61⋅7 per cent in
2007–2010 to 31 per cent in 2011–2013 (P < 0⋅001). No
patient treated with PME developed local recurrence when
a DRM of at least 3⋅5 cm was achieved (Table 3).
Inadvertent residual mesorectum was identified in 163
(42⋅8 per cent) of the 381 patients who had postoperative
MRI. In patients who underwent PME, inadvertent
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Fig. 1 Actuarial local recurrence rates by tumour height in the two time periods
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Table 3 Subanalysis of risk factors for local recurrence in patients with cancer of the upper rectum
2007–2010 2011–2013
No. of
patients
(n=141)
3-year
actuarial local
recurrence (%)
No. of patients
(n=101)
3-year
actuarial local
recurrence (%) P*
Type of surgery
PME 128 (90⋅8) 13⋅3 81 (80⋅2) 6⋅3 0⋅028
TME 13 (9⋅2) 0⋅0 20 (19⋅8) 0⋅0 –
pT category
pT0–2 32 (22⋅7) 3⋅9 22 (21⋅8) 0⋅0 –
pT3 84 (59⋅6) 17⋅6 65 (64⋅4) 4⋅2 0⋅071
pT4 25 (17⋅7) 29⋅6 13 (12⋅9) 25⋅0 0⋅925
Missing 0 (0) – 1 (1⋅0) – –
CRM
Negative 128 (90⋅8) 11⋅5 91 (90⋅1) 4⋅2 0⋅081
Positive 13 (9⋅2) 28⋅6 9 (8⋅9) 13⋅3 0⋅834
Missing 0 (0) – 1 (1⋅0) – –
DRM pathology (only for PME) n=128 n=81
<3⋅5 cm 79 (61⋅7) 20⋅2 25 (31) 10 0⋅163
≥3⋅5 cm 43 (33⋅6) 0⋅0 55 (68) 0 –
Missing 6 (4⋅7) – 1 (1) – –
Surgical approach
Laparotomy 116 (82⋅3) 13⋅8 21 (20⋅8) 0⋅0 0⋅125
Laparoscopy 25 (17⋅7) 9⋅5 80 (79⋅2) 6⋅4 0⋅786
Values in parentheses are 95 per cent confidence intervals. PME, partial mesorectal excision; TME, total mesorectal excision; CRM, circumferential
resection margin; DRM, distal resection margin. *Log rank test.
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Fig. 2 Sagittal T2-weighted MRI of the pelvis
a  Preoperative MRI of mrT4 tumour b  Postoperative MRI showing axial recurrence
a Preoperative MRI showing an mrT4 tumour (orange area) estimated to be located 8 cm from the anal verge on MRI, but which was measured by rigid
proctoscopy before surgery to be located 12 cm from the anal verge. The red arrow denotes the height of tumour invasion. The patient was selected for
partial mesorectal excision without preoperative radiochemotherapy. b Postoperative MRI 6 months after primary surgery in 2009, showing axial recurrence
(orange) at the anastomosis (white dashed line). Suboptimal surgery with a distal resection margin of 8 mm was found on histopathological examination.
Fig. 3 Sagittal T2-weighted MRI of the pelvis
a  Preoperative MRI of mrT3 tumour b  Postoperative MRI
a Preoperative MRI showing an mrT3 tumour located 14⋅8 cm from the anal verge in the upper rectum (orange area). The red arrow denotes the height
of tumour invasion. b Postoperative MRI shows the plane of dissection and level of anastomosis (white dashed line). Only mesorectum below the level of
the anastomosis is observed in a distance of more than 3⋅5 cm from the primary tumour.
residual mesorectum was detected in 60⋅4 per cent (84
of 139). This did not differ between 2007–2010 and
2011–2013: 60 per cent (50 of 84) and 62 per cent (34
of 55) respectively (P = 0⋅458). The mean volume of
inadvertent residual mesorectum was 8⋅03 and 5⋅74 cm3 in
2007–2010 and 2011–2013 respectively (P = 0⋅250).
Based on the preoperative tumour status (mrT), T4 dis-
ease was overrepresented in patients with local recurrence
© 2019 The Authors. www.bjsopen.com BJS Open
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who underwent PME or APE. All pT4 tumours of the
upper rectum were due to local peritoneal involvement
(pT4a).
In 2007–2010 and 2011–2013, long-course preoperative
radiochemotherapy was administered in 24⋅6 per cent (31
of 126) and 22⋅5 per cent (25 of 111) respectively of patients
who had TME, and in 62⋅4 per cent (68 of 109) and
51 per cent (37 of 72) of those who underwent APE. In
patients who had PME, neoadjuvant therapy was not used
in 2007–2010, whereas it was employed in 4 per cent (3 of
81) of patients who underwent PME in 2011–2013.
Discussion
This study has shown a significant reduction in the risk
of local recurrence after a local MDT-directed quality
assurance programme in patients with cancer of the upper
rectum. A previous report11 on local recurrence in patients
who had PME for upper rectal cancer was disappointing,
and suboptimal surgery and/or selection was evident.
To obtain and maintain improvements in quality of rectal
cancer surgery, it may be necessary to consolidate the
training by organizing continuous workshops with a focus
on difficulties in the current treatment of rectal cancer, in
order to sustain best quality treatment in routine clinical
practice. By using postoperative MRI, it is possible to assess
the extent and completeness of mesorectal excision, to
highlight difficulties in current management of upper rectal
cancer. One of the great hallmarks of MDT collaboration
is quality assurance and internal audit of the quality of
treatment performed.
For cancer of the upper rectum, it remains unsettled as
to whether TME is necessary, or whether PME is ade-
quate. Unfortunately, the major studies investigating the
initial improvements following the introduction of TME
have not specifically distinguished the type of procedure
for upper rectal cancer, hindering comparison19. It is clear,
however, that the less extensive PME with preservation of a
distal part of remnant rectum offers a better functional out-
come and lower risk of anastomotic leakage1,2,20. Dedicated
single centres have shown that with skilful surgery it is pos-
sible with PME to achieve low local recurrence rates, equal
to or better than the local recurrence rates achieved with
TME, and without the use of neoadjuvant therapy2,3,7,8.
Based on data from the Stockholm Colorectal Cancer
Study Group, Syk and colleagues21,22 reported a crude
local recurrence rate of 9 per cent in patients who under-
went PME for upper rectal cancer, despite the wide use
of preoperative short-course radiotherapy. Rosenberg and
co-workers12 performed PME for all tumours of the upper
rectum and observed a 5-year local recurrence rate of 15⋅5
per cent, not significantly different from that for mid-rectal
tumours, but worse than for sigmoid cancer. Similarly,
Kodeda et al.13 reported a crude 5-year local recurrence
rate of 14⋅4 per cent for tumours of the upper rectum
without routine preoperative radiotherapy in their regional
cohort, compared with a local recurrence rate of 5⋅5 per
cent from the Swedish Rectal Cancer Registry.
The risk of local recurrence in patients with upper rec-
tal cancer treated in 2007–2010 corresponds to the results
presented by Syk and colleagues22, in which CT and
MRI images from 99 patients with local recurrence were
analysed. In the group of patients with local recurrence,
residual mesorectum was observed in 86 per cent on post-
operative MRI. The authors suggested that an intentional
or inadvertent PME, combined with the omission of radio-
therapy, was the main cause of recurrence in these patients.
An effort to detect suboptimal surgery with postopera-
tive imaging was attempted before the advent of modern
MRI. By using postoperative angiography of the mesen-
teric artery, Hohenberger and co-workers23 observed that
the inferior mesenteric artery and superior rectal artery
remained together with adjacent mesorectal fatty tissue
after coning of the mesorectum.
In a recent educational tutorial by Kuzu et al.24, Heald
stated that during a PME the rectum and mesorectum
should be mobilized at least 8 cm below the level of the
tumour to achieve an adequate margin in the fresh spec-
imen of at least 5 cm. The fact that no patient who under-
went PME with a distal margin greater than 3⋅5 cm devel-
oped local recurrence, compared with 17⋅7 per cent of
patients with a shorter distal margin, further supports
this recommendation. In 2012, Jullumstrø and colleagues25
analysed 394 patients in a Norwegian cohort with regard to
violation of treatment guidelines. The risk of local recur-
rence was 11 per cent after curative resection with a distal
clearance of less than 2 cm, compared with only 3 per cent
when distal clearance was more than 2 cm.
Kusters and co-workers19 analysed the patients with local
recurrence in the Dutch TME Trial and found that most
local recurrences were located in relation to the anastomo-
sis, especially in the patients without the otherwise greatest
risk factors (T4 tumour, N2 disease and involved CRM).
Local recurrence in relation to the anastomosis is gener-
ally considered to be the result of inadequate or subop-
timal surgery, with failure of complete surgical removal
of the primary tumour or its initial field of spread in the
mesorectum19,26–28.
No difference in the reported prevalence of inadvertent
residual mesorectum on postoperative MRI was observed
in the present study after the workshop, despite the
observed improvement in local recurrence. Small amounts
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of residual mesorectum in sufficient clearance of the pri-
mary tumour may not be associated with an increased
risk of local recurrence, similar to pathology reports that
an intramesorectal excision may not be associated with
an increased risk of local recurrence compared with that
following complete mesorectal excision29,30.
There is ongoing controversy as to whether patients
with cancer of the upper rectum will benefit from neoad-
juvant therapy. In Denmark, only patients with unre-
sectable cancer of the upper rectum are considered for
neoadjuvant therapy, as opposed to those with advanced
mid or low rectal cancer. Large population-based studies
from Sweden have reported that more than 60 per cent
of patients with rectal cancer received neoadjuvant ther-
apy, including 43–58 per cent of patients with tumours
located in the upper rectum, and more than 40 per cent of
those with T1–2 tumours15,31. In 2011, Tiefenthal et al.15
showed an effect on local recurrence risk with preopera-
tive short-course radiotherapy for upper rectal tumours in a
national population-based study. Advanced tumours of the
upper rectum can be staged accurately using MRI and also
possibly downstaged with neoadjuvant therapy32,33.
The characterization of rectal cancer into high, mid and
low lesions is traditionally measured from the anal verge
using a rigid proctoscope. Although this measurement is
mandatory in Denmark, it may vary depending on the
surgeon performing the examination, the patient and the
method34. Confident localization of a rectal tumour is
increasingly important, especially in relation to treatment
guidelines, as the differentiation between mid or upper
rectum has a significant impact on the decision to allocate
for neoadjuvant therapy.
In their 2016 annual report35 on colorectal cancer
management in Denmark, the Danish Colorectal Cancer
Group reported that 20 per cent of 377 tumours located
in the upper rectum, when measured by rigid proctoscopy,
were found to be located in the mid rectum on preop-
erative MRI. The English National Low Rectal Cancer
Development Programme36 has suggested a new definition
of low rectal cancer as a tumour with its distal margin at
or below the level of origin of the levators on the pelvic
side-wall. In the same way, because division of the rectum
by strict centimetre criteria seems unrealistic on an indi-
vidual basis, tumours of the upper rectum were defined by
anatomical landmarks appreciable on preoperative MRI,
such as the level of the peritoneal reflection or length of
the mesorectum to the pelvic floor37,38. By relying more on
preoperative MRI to determine the location of the tumour
in the rectum, fewer patients were selected to undergo
PME. In advanced cases there may be an increased risk
when leaving behind mesorectum. Similar findings were
reported by Chang and colleagues39 in a study that used
MRI to identify high-risk patients with upper rectal cancer.
In the present authors’ opinion, the height of the tumour
is assessed most reliably by preoperative MRI, and can be
used to determine whether PME or TME is preferable.
By using the Delphi method, the European Registration
of Cancer Care40 has recommended MRI as the method
of choice for assessing tumour height and location in the
rectum in multidisciplinary treatment of rectal cancer.
Limitations of the present study include the differences
in the baseline characteristics between the patient cohorts
in the two time periods, and that the implementation of
laparoscopic surgery in the second period may also have
potentially influenced outcomes. All MRI examinations
were evaluated by the same radiologist in consensus with
the first author. No previous analyses on interobserver vari-
ability have been reported. In a recent study by Veltcamp
Helbach et al.10, two radiologists evaluated the MRI images
independently. After the first evaluation, there was agree-
ment of the radiologists in 59⋅4 per cent of cases. After
consensus reading, consensus was reached in all patients
as the radiologists became more familiar with identifying
residual mesorectum on MRI, which implicates a learning
curve. In the present study, residual mesorectum was con-
sidered to be present only when consensus was achieved.
A national audit of the quality of surgery in Denmark is
currently being conducted including postoperative MRI,
and a training programme for colorectal surgeons with a
specific focus on surgery for upper rectal cancer is planned.
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